GLI1 and neoplasm: Daily administration of GDC-0941 at the dosage of 150 mg/kg significantly reduced the tumor growth in both sensitive and resistant models, indicating that these tumors are dependent on the non-canonical PI3K signaling to maintain GLI activation.